Armour Therapeutics Inc. (ATI) is an Ontario biopharmaceutical company leading the development of a new class of anti-cancer therapeutics. Armour is developing a non-androgen, anti-hormone therapy for patients who develop hormone-refractory prostate cancer. Exhibiting cytostatic and anti-angiogenic properties, Armour's lead compound, AT-001, targets a new hormonal pathway that has the potential to offer a synergistic therapeutic benefit to impair tumor growth and prolong patient survival. Armour's anti-hormone therapy is proposed to be employed as either a monotherapy or in conjunction with marketed anti-androgen therapies and chemotherapeutics to suppress malignant tumors in mid-stage to end-stage prostate cancer.